Post-Stroke Hemiplegia (Investigational Adjunct)
Investigational adjunct to physical/occupational therapy in chronic post-stroke hemiplegia; no RCT support; not for acute stroke care.
Patient Summary
- Is this FDA-cleared for this use?
- Not FDA-cleared for post-stroke hemiplegia. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use for post-stroke hemiplegia is investigational.
- What evidence exists?
- Tier C (investigational). Only small, low-quality reports were identified, mostly Russian-language and including an uncontrolled series of 89 patients whose leech treatment was part of a combined rehabilitation program; no randomized controlled trial was identified. Evidence-based stroke rehabilitation per AHA/ASA guidelines: structured inpatient or outpatient rehabilitation, constraint-induced movement therapy, repetitive task training, mirror therapy, robot-assisted therapy, functional electrical stimulation, and botulinum toxin for spasticity. Antiplatelet (aspirin, clopidogrel) or anticoagulant therapy for secondary prevention. Statin, blood pressure control, and lifestyle modification.
- Main risks
- Bleeding from bite sites for 6 to 24 hours after detachment, prolonged on antiplatelet or anticoagulant
- Severe bleeding risk on dual antiplatelet or anticoagulant therapy (post-stroke standard)
- Worsening of spasticity or neurogenic pain
- Local skin infection or, rarely, Aeromonas infection
- Allergic reaction to leech saliva (uncommon)
- Risk in patients with marginal cerebral perfusion (transient symptom worsening)
- Substitution for evidence-based rehabilitation and secondary prevention
- Delay of constraint-induced movement therapy, botulinum toxin for spasticity, or rehab milestones
- Who should not consider this
- Patients within 3 months of acute stroke (recovery window — focus on rehab)
- Patients with severe spasticity or contracture requiring physiatry evaluation
- Patients with active depression, post-stroke psychiatric symptoms (treat first)
- Patients on anticoagulants, with hemophilia, or with anemia (aspirin and clopidogrel, alone or together, are not a contraindication by themselves: tell your doctor, who starts with fewer leeches)
- Patients who have not engaged with structured stroke rehabilitation
- What to ask your clinician
- Am I engaged with structured outpatient stroke rehabilitation?
- Have I been offered constraint-induced movement therapy or robot-assisted therapy?
- Am I a candidate for botulinum toxin injection for spasticity?
- What are my current antiplatelet or anticoagulant therapies, and is the bleeding risk acceptable?
- What evidence specifically supports leech therapy for stroke recovery?
- Has my secondary prevention been optimized (statin, blood pressure, lifestyle)?
- What is the cost and is it covered by insurance? (typically not covered)
- When to seek urgent care
- Sudden new weakness, numbness, slurred speech, or vision loss (possible recurrent stroke)
- Sudden severe headache (worst of life — rule out hemorrhage)
- Chest pain, shortness of breath (possible cardiac event)
- Severe bleeding from any site (anticoagulant overdose or interaction)
- Spreading redness, warmth, pus, or red streaks (cellulitis)
- Fever above 38.0 C / 100.4 F or chills
- Bleeding from a bite site lasting more than 24 hours
- Hives, facial or tongue swelling, throat tightness, or breathing difficulty
What this does NOT mean
- This is NOT FDA-cleared for post-stroke hemiplegia.
- Small, uncontrolled reports do NOT establish efficacy versus structured rehabilitation, constraint-induced movement therapy, or botulinum toxin.
- It does NOT substitute for evidence-based stroke rehab during the critical recovery window.
- It does NOT address antiplatelet or anticoagulant therapy that is essential for secondary prevention — and these therapies make leech bleeding much more dangerous.
- It does NOT replace structured rehabilitation that has decades of evidence.
Safety cross-references
Clinical Profile
- Category
- Neurological
- ICD-10
- I69.351, I69.352, I69.353, I69.359
- Safety tier
- High
Evidence Summary
Post-stroke hemiplegia management is dominated by neurorehabilitation (constraint-induced movement therapy, mirror therapy, robotic rehabilitation, task-specific training) per AHA/ASA 2016 guidelines. No randomized controlled trial of leech therapy for post-stroke hemiplegia was identified in PubMed, Europe PMC or ClinicalTrials.gov. Small Russian-language reports exist but are low in quality: an uncontrolled series of 89 patients with sequelae of ischemic stroke treated with leeches inside a combined rehabilitation program (Frolov and Frolova 1999, conference proceedings cited in Baskova and Isakhanyan 2004), and a few small comparisons in the acute stage of stroke (for example 30 treated and 32 comparison patients with small intracerebral hemorrhage, Teshabaev 2017). None separates an effect of leeches on motor recovery from the accompanying rehabilitation, so leech therapy has no established role in motor recovery; any use would be investigational only. A critical safety constraint applies: most post-stroke patients take antiplatelet or anticoagulant therapy for secondary prevention, an absolute exclusion for leech therapy. Leech application is not a substitute for evidence-based rehabilitation.
What the books describe
Below is a summary of what books on hirudotherapy say about this condition. These are the authors’ observations, not a proven effect and not a promise of results. Hirudotherapy has contraindications; the decision is made by a physician.
- Baskova and Isakhanyan retell observations by V. A. Frolov and E. A. Frolova (1999) of 89 patients with the after-effects of ischemic stroke: leeches were one part of a rehabilitation program that also included reflexotherapy, medications, massage and therapeutic exercise[B1].
- According to this description, in 28 patients movement in the paralyzed limbs was fully restored, in 6 muscle tone and tendon reflexes decreased without signs of recovery of movement, and in the rest, after treatment, muscle strength in the limbs corresponded to 1–4 points[B1].
- Because the leeches were given together with other methods, it is not clear from this description what they contributed on their own; a comparison group, the time from stroke to the start of treatment and the follow-up period are not named[B1].
- Among the contraindications, Baskova and Isakhanyan name hemophilia, anemias, low blood pressure, cachexia, concurrent use of anticoagulants, especially long-term and daily, and concurrent alcohol consumption[B1].
- Flecken and Michalsen regard taking anticoagulants (warfarin, heparin and others) as an absolute contraindication, and aspirin and clopidogrel not as contraindications in themselves: in that case fewer leeches are used in the first session and the patient is asked about bleeding tendencies[B3].
- Michalsen et al. describe two cases in which patients with high blood pressure who were taking three antihypertensive drugs had a brief fainting episode a few hours after leeches; they remind readers that leeches themselves lower blood pressure, advise drinking plenty of fluids and, if the wound bleeds heavily, monitoring blood pressure and adjusting the antihypertensive drugs if necessary[B3].
- Michalsen et al. do not write about recovery of movement after stroke: stroke is mentioned by them only in the section on hypertension and cardiovascular diseases, where it says that in the first half of the twentieth century leeches were commonly used for stroke and heart attack, and that after the advent of aspirin the importance of the method declined rapidly; paralysis and hemiplegia as an indication are not mentioned[B3].
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: where the society's reference books describe a protocol, it is shown in the clinician view — switch the audience selector in the top bar to “Clinician”.)
Contraindications
- Hemophilia or another bleeding disorder
- Taking anticoagulants (blood thinners such as warfarin or heparin)
- Anemia or suppressed blood formation
- Low blood pressure, shock, collapse or fainting
- Severe wasting (cachexia)
- Intolerance of leeches or a history of severe allergic reactions
- Pregnancy
- Stomach or duodenal ulcer, erosive gastritis
- Acute infectious disease or high fever
- Severe unstable illness, markedly weakened immunity (for example during chemotherapy) or HIV infection
- Drinking alcohol at the time of treatment
- No consent from the patient
- Active deep vein thrombosis (acute phase)
- Critical limb ischemia (ABI <0.4)
- Acute or subacute stroke (<3 months from onset)
- Hemorrhagic stroke history
- Uncontrolled hypertension (SBP >180)
- Severe cognitive impairment limiting consent
Related Conditions
Spasticity Post-Spinal Cord Injury (Investigational Adjunct)
Investigational adjunct for muscular spasticity after SCI; no clinical study identified; baclofen (oral or intrathecal) and physiotherapy remain primary.
Multiple Sclerosis Fatigue (Investigational Adjunct)
Investigational adjunct for MS-related fatigue; no clinical study was identified; disease-modifying therapy and modafinil/amantadine remain primary.
Complex Regional Pain Syndrome (Type I, Investigational)
Highly investigational adjunct for CRPS Type I; one case report and no controlled study identified; multidisciplinary pain management and physiotherapy remain primary.
Cervical Radiculopathy
Investigational use for cervical radiculopathy; no verifiable published trial specific to this indication.
References
- [B1]
Баскова И.П., Исаханян Г.С. Гирудотерапия. Наука и практика [Hirudotherapy: Science and Practice]
Monograph in Russian, 506 pp., ISBN 5-89527-058-1. Chapter 15: sensation at the bite, length of the session; secretion kininases and pain.
- [B3]
Michalsen A., Roth M., Dobos G. Medicinal Leech Therapy
ISBN 978-3-13-143581-1 / 978-1-58890-563-5. Chapter 9, p. 107: perceptions of the bite — a local dragging pain lasting around one to five minutes.
The information on this page is based on the hirudotherapy books listed under References and reflects the experience their authors describe. Sensations and results differ from person to person. This information is not medical advice, a diagnosis or a prescription, and it does not replace an examination by a physician. Do not stop or change any prescribed treatment without your physician. Hirudotherapy has contraindications.